Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis
Edinburgh and London, UK, 10 December 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company focused on pioneering regenerative macrophage therapy (“RMT”) in inflammatory and fibrotic diseases, today announces it has presented a poster at the Keystone Symposia Fibrosis: Inflammation, Drivers, and Therapeutic Resolution taking place on 8 – 11 December 2024 in Whistler, BC, Canada.
The company presented data from its unique combination of cell-based assays and preclinical in vivo experiments conducted to fulfil the regulatory requirements for the initiation of first-in-human trials. EMERALD, a Phase 1/2 study of multi-dose engineered macrophages to treat end-stage liver disease (ESLD), will be the first time engineered macrophages are used to potentially reverse fibrosis. The preclinical strategy presented in this poster led the UK and Spain health authorities to approve the clinical trial application for RTX001 in end-stage liver disease earlier this year. EMERALD is currently actively recruiting patients.
Details of the poster presentation:
Title: Nonclinical program to enable a Phase1/2 trial of engineered pro-regenerative macrophages for the treatment of end stage liver disease.
Publication Number: 1044
Session Date and Time: Poster Session #1, 9th of December, 7:30:00 PM (GMT-8)
Presenter: Keith Sutton, PhD – Director, Pre-Clinical Development at Resolution Therapeutics
